medigraphic.com
ISSN 2078-7170 (Digital)

2020, Número 1

<< Anterior Siguiente >>

CorSalud 2020; 12 (1)


Repercusión cardiovascular de la infección por el nuevo coronavirus SARS-CoV-2 (COVID-19)

Moreno-Martínez FL, Moreno-López FL, Oroz MR

Idioma: Español
Referencias bibliográficas: 71
Paginas: 3-17
Archivo PDF: 1288.14 Kb.


FRAGMENTO

El 7 de enero de 2020, el nuevo coronavirus SARSCoV-2 (severe acute respiratory syndrome coronavirus 2) fue oficialmente reconocido por las autoridades chinas como el agente causal de una serie de casos de neumonía diagnosticados en Wuhan, China, durante el mes previo (diciembre/2019). La enfermedad que produce este virus ha sido nombrada, en su idioma original, Novel Coronavirus Infectious Disease 2019, de donde surge su conocido acrónimo COVID-19; fue declarada por la Organización Mundial de la Salud (OMS) como una emergencia de salud pública internacional el 30 de enero de 20202, y como una pandemia el 11 de marzo siguiente.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Palacios Cruz M, Santos E, Velázquez Cervantes MA, León Juárez M. COVID-19, una emergencia de salud pública mundial. Rev Clin Esp [Inter-net]. 2020 [Online 20 Mar 2020]. Available at: https://doi.org/10.1016/j.rce.2020.03.001

  2. World Health Organization. 2019-nCoV outbreak is an emergency of international concern [Inter-net, publicado 31 Ene 2020]. World Health Organ-ization, Regional Office for Europe [cited 28 Mar 2020]. Available at: http://www.euro.who.int/en/health-topics/health-emergencies/international-health-regulations/news/news/2020/2/2019-ncov-outbreak-is-an-emergency-of-international-concern

  3. World Health Organization. WHO Director-Gen-eral's opening remarks at the media briefing on COVID-19 - 11 March 2020 [Internet, publicado 11 Mar 2020]. World Health Organization [cited 28 Mar 2020]. Available at: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020

  4. Heymann DL, Shindo N; WHO Scientific and Technical Advisory Group for Infectious Hazards. COVID-19: what is next for public health? Lancet. 2020;395(10224):542-5.

  5. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating per-son-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514-23.

  6. Coronavirus Resource Center. COVID-19 Dash-board by the Center for Systems Science and En-gineering (CSSE) at Johns Hopkins University (JHU) [Internet]. Johns Hopkins University of Medicine [cited 12 Apr 2020]; 2020. Available at: https://coronavirus.jhu.edu/map.html

  7. World Health Organization. Coronavirus (COVID-19) – WHO Health Emergency Dashboard [Inter-net]. 2020 [cited 12 Apr 2020]. Available at: https://covid19.who.int/

  8. Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr. 2020;14(3):247-50.

  9. Paules CI, Marston HD, Fauci AS. Coronavirus Infections-More Than Just the Common Cold. JAMA. 2020;323(8):707-8.

  10. Cui J, Li F, Shi ZL. Origin and evolution of patho-genic coronaviruses. Nat Rev Microbiol. 2019; 17(3):181-92.

  11. Cossarizza A, De Biasi S, Guaraldi G, Girardis M, Mussini C; Modena Covid-19 Working Group (MoCo19)#. SARS-CoV-2, the Virus that Causes COVID-19: Cytometry and the New Challenge for Global Health. Cytometry A. 2020;97(4):340-3.

  12. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res [Internet]. 2020 [Online 13 Mar 2020]; 7(1):11. Available at: https://doi.org/10.1186/s40779-020-00240-0

  13. van Doremalen N, Bushmaker T, Morris DH, Hol-brook MG, Gamble A, Williamson BN, et al. Aero-sol and surface stability of SARS-CoV-2 as com-pared with SARS-CoV-1. N Engl J Med. 2020; 382(16):1564-7.

  14. Huang Y, Chen S, Yang Z, Guan W, Liu D, Lin Z, et al. SARS-CoV-2 Viral Load in Clinical Samples of Critically Ill Patients. Am J Respir Crit Care Med. 2020 [Online 15 Apr 2020]. Available at: https://doi.org/10.1164/rccm.202003-0572le

  15. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease. Circula-tion [Internet]. 2020 [Online 21 Mar 2020]. Avail-able at: http://doi.org/10.1161/CIRCULATIONAHA.120.046941

  16. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 viral load in upper respirato-ry specimens of infected patients. N Engl J Med. 2020;382(12):1177-9.

  17. Pérez Assef A, Rivero Martínez HB, Pereda Gon-zález R, Breto García A, Piloto Padrón M, Oviedo Rodríguez R. Protocolo para el tratamiento de la enfermedad por COVID-19 (SARS-CoV-2) en pa-cientes obstétricas ingresadas en cuidados inten-sivos. Rev Cuban Med Int Emerg [Internet]. 2020 [cited 10 Apr 2020];19(2):e745. Available at: http://www.revmie.sld.cu/index.php/mie/article/view/745/pdf

  18. Yang H, Wang C, Poon LC. Novel coronavirus in-fection and pregnancy. Ultrasound Obstet Gyne-col. 2020;55(4):435-7.

  19. Chen D, Yang H, Cao Y, Cheng W, Duan T, Fan C, et al. Expert consensus for managing pregnant women and neonates born to mothers with sus-pected or confirmed novel coronavirus (COVID-19) infection. Int J Gynaecol Obstet. 2020;149(2): 130-6.

  20. Kimberlin DW, Stagno S. Can SARS-CoV-2 Infec-tion Be Acquired In Utero?: More Definitive Evi-dence Is Needed. JAMA [Internet]. 2020 [Online 26 Mar 2020]. Available at: https://doi.org/10.1001/jama.2020.4868

  21. Liu W, Wang J, Li W, Zhou Z, Liu S, Rong Z. Clini-cal characteristics of 19 neonates born to mothers with COVID-19. Front Med [Internet]. 2020 [On-line 13 Apr 2020]. Available at: https://doi.org/10.1007/s11684-020-0772-y

  22. Pérez G. Coronavirus y su impacto cardiovascu-lar [Internet, publicado 22 Mar 2020]. Sociedad Interamericana de Cardiología [cited 30 Mar 2020]. Available at: http://www.siacardio.com/novedades/covid-19/coronavirus-y-su-impacto-cardiovascular/

  23. Vaira LA, Salzano G, Deiana G, De Riu G. Anosmia and Ageusia: Common Findings in COVID-19 Pa-tients [Internet]. Laryngoscope. 2020 [Online 1 Apr 2020]. Available at: https://doi.org/10.1002/lary.28692

  24. Mehta P, McAuley DF, Brown M, Sanchez E, Tat-tersall RS, Manson JJ. COVID-19: consider cyto-kine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-4.

  25. Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, et al. Cardiac involvement in a pa-tient with Coronavirus Disease 2019 (COVID-19). JAMA Cardiol [Internet]. 2020 [Online 27 Mar 2020]. Available at: http://doi.org/10.1001/jamacardio.2020.1096

  26. Siddiqi HK, Mehra MR. COVID-19 Illness in Native and Immunosuppressed States: A Clinical-Thera-peutic Staging Proposal. J Heart Lung Transplant [Internet]. 2020 [Online 20 Mar 2020]. Available at: https://doi.org/10.1016/j.healun.2020.03.012

  27. Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J [In-ternet]. 2020 [Online 28 Mar 2020]:ehaa231. Avail-able at: https://doi.org/10.1093/eurheartj/ehaa231

  28. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506.

  29. Yang C, Jin Z. An Acute Respiratory Infection Runs Into the Most Common Noncommunicable Epidemic-COVID-19 and Cardiovascular Diseases. JAMA Cardiol [Internet]. 2020. [Online 25 Mar 2020]. Available at: http://doi.org/10.1001/jamacardio.2020.0934

  30. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223):507-513.

  31. Bonow RO, Fonarow GC, O'Gara PT, Yancy CW. Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality. JAMA Cardiol [Internet]. 2020 [Online 27 Mar 2020]. Available at: http://doi.org/10.1001/jamacardio.2020.1105

  32. @Cardio_delaGuia (Fernando de la Guía). Hipó-tesis de Lesión Cardíaca Aguda #Covid19 #coro-navirus [Internet]. Post in Twitter 19 Mar 2020 [cit-ed 11 Abr 2020]. Retrieved from: https://twitter.com/Cardio_delaGuia/status/1240584448241852416

  33. Chen YD, Li YZ, Liu XH, Zhou H. Potential patho-physiological mechanisms underlying COVID-19-induced myocardial injury. Chin J Pathophysiol. 2020;36(3):573-6.

  34. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020; 17(5):259-60.

  35. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol [Internet]. 2020 [Online 27 Mar 2020]:e201017. Available at: https://doi.org/10.1001/jamacardio.2020.1017

  36. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol [Internet]. 2020 [Online 25 Mar 2020]:e200950. Available at: http://doi.org/10.1001/jamacardio.2020.0950

  37. Fried JA, Ramasubbu K, Bhatt R, Topkara VK, Clerkin KJ, Horn E, et al. The variety of cardio-vascular presentations of COVID-19. Circulation [Internet]. 2020. [Online 3 Apr 2020]. Available at: http://doi.org/10.1161/CIRCULATIONAHA.120.047164

  38. Corrales-Medina VF, Alvarez KN, Weissfeld LA, Angus DC, Chirinos JA, Chang CC, et al. Associa-tion between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA. 2015;313(3):264-74.

  39. Hulot JS. COVID-19 in patients with cardiovascu-lar diseases. Arch Cardiovasc Dis. 2020 Apr; 113(4):225-6.

  40. Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. Evolution of the novel coronavirus from the on-going Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020;63(3):457-60.

  41. Fung G, Luo H, Qiu Y, Yang D, McManus B. Myo-carditis. Circ Res. 2016;118(3):496-514.

  42. Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis treated with glucocorticoid and hu-man immunoglobulin. Eur Heart J [Internet]. 2020 [Online 16 Mar 2020]:ehaa190. Available at: https://doi.org/10.1093/eurheartj/ehaa190

  43. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Car-diovascular System: A Review. JAMA Cardiol [In-ternet]. 2020 [Online 27 Mar 2020]. Available at: https://doi.org/10.1001/jamacardio.2020.1286

  44. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth Universal Defini-tion of Myocardial Infarction (2018). J Am Coll Cardiol. 2018;72(18):2231-64.

  45. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid anti-bodies in patients with Covid-19. N Engl J Med [Internet]. 2020 [Online 23 Apr 2020];382(17): e38. Available at: https://doi.org/10.1056/nejmc2007575

  46. Gauna ME, Bernava JL. Recomendaciones diag-nósticas y terapéuticas ante la Respuesta Inmune Trombótica Asociada a Covid-19 (RITAC). CorSa-lud [Internet]. 2020 [cited 1 Apr 2020];12(1):60-63. Available at: http://www.revcorsalud.sld.cu/index.php/cors/article/view/615/1110

  47. Carter SJ, Tattersall RS, Ramanan AV. Macro-phage activation syndrome in adults: recent ad-vances in pathophysiology, diagnosis and treat-ment. Rheumatology (Oxford). 2019;58(1):5-17.

  48. Karakike E, Giamarellos-Bourboulis EJ. Macro-phage Activation-Like Syndrome: A distinct entity leading to early death in sepsis. Front Immunol [Internet]. 2019 [cited 10 Apr 2020];10:55. Avail-able at: https://doi.org/10.3389/fimmu.2019.00055

  49. Chousterman BG, Swirski FK, Weber GF. Cyto-kine storm and sepsis disease pathogenesis. Semin Immunopathol. 2017;39(5):517-28.

  50. Channappanavar R, Perlman S. Pathogenic hu-man coronavirus infections: causes and conse-quences of cytokine storm and immunopatholo-gy. Semin Immunopathol. 2017;39(5):529-39.

  51. Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the Ameri-can College of Cardiology/American Heart Asso-ciation Task Force on Clinical Practice Guide-lines. Circulation. 2019;139(14):e698-e800.

  52. Tan W, Aboulhosn J. The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a fo-cus on congenital heart disease. Int J Cardiol [In-ternet]. 2020 [Online 28 Mar 2020]. Available at: https://doi.org/10.1016/j.ijcard.2020.03.063

  53. Romaguera R, Cruz-González I, Jurado-Román A, Ojeda S, Fernández-Cisnal A, Jorge-Pérez P, et al. Consideraciones sobre el abordaje invasivo de la cardiopatía isquémica y estructural durante el brote de coronavirus COVID-19. Documento de consenso de la Asociación de Cardiología Inter-vencionista y la Asociación de Cardiopatía Is-quémica de la Sociedad Española de Cardiología. REC Interv Cardiol [Internet]. 2020 [Online 25 Mar 2020]. Available at: https://doi.org/10.24875/RECIC.M20000119

  54. Romaguera R, Cruz-González I, Ojeda S, Jiménez-Candil J, Calvo D, García Seara J, et al. Gestión de las salas de procedimientos invasivos cardiológi-cos durante el brote de coronavirus COVID-19. Documento de consenso de la Asociación de Cardiología Intervencionista y la Asociación del Ritmo Cardiaco de la Sociedad Española de Car-diología. REC Interv Cardiol [Internet]. 2020 [On-line 27 Mar 2020]. Available at: https://doi.org/10.24875/RECIC.M20000114

  55. Welt FGP, Shah PB, Aronow HD, Bortnick AE, Henry TD, Sherwood MW, et al. Catheterization laboratory considerations during the Coronavirus (COVID-19) Pandemic: From ACC's Interventional Council and SCAI. J Am Coll Cardiol [Internet]. 2020 [Online 19 Mar 2020]. Available at: http://doi.org/10.1016/j.jacc.2020.03.021

  56. Han Y, Zeng H, Jiang H, Yang Y, Yuan Z, Cheng X, et al. CSC Expert Consensus on Principles of Clin-ical Management of patients with severe emer-gent cardiovascular diseases during the COVID-19 Epidemic. Circulation [Internet]. 2020. [Online 27 Mar 2020]. Available at: http://doi.org/10.1161/CIRCULATIONAHA.120.047011

  57. 57.Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in pa-tients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Present-ing without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267-315.

  58. Gómez Guindal JA. Protocolo de atención a pa-cientes con síndrome coronario agudo en el Hos-pital de Fuerteventura durante la pandemia de COVID-19. CorSalud [Internet]. 2020 [cited 1 Apr 2020];12(1):109-113. Available at: http://www.revcorsalud.sld.cu/index.php/cors/article/view/604/1111

  59. Patel MR, Calhoon JH, Dehmer GJ, Grantham JA, Maddox TM, Maron DJ, et al. ACC/AATS/AHA/ ASE/ASNC/SCAI/SCCT/STS 2016 Appropriate Use Criteria for Coronary Revascularization in Pa-tients With Acute Coronary Syndromes: A Report of the American College of Cardiology Appropri-ate Use Criteria Task Force, American Associa-tion for Thoracic Surgery, American Heart Asso-ciation, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interven-tions, Society of Cardiovascular Computed To-mography, and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2017;69(5):570-91.

  60. Barja LD, Fitz Maurice M, Chávez González E. Hidroxicloroquina y azitromicina: riesgo cardio-vascular, prolongación de QTc y muerte súbita en el nuevo escenario de la pandemia por CO-VID-19. CorSalud [Internet]. 2020 [cited 31 Mar 2020];12(1):54-59. Available at: http://www.revcorsalud.sld.cu/index.php/cors/article/view/601/1108

  61. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med [Internet]. 2020 [Onli-ne 3 Mar 2020]. Available at: https://doi.org/10.1007/s00134-020-05991-x

  62. Vetta F, Vetta G, Marinaccio L. Coronavirus Dis-ease 2019 (COVID-19) and Cardiovascular Dis-ease: A Vicious Circle. J Cardiol Cardiovasc Res [Internet]. 2020 [cited 12 Apr 2020];1(2):1-12. Avai-lable at: https://maplespub.com/webroot/files/Coronavirus-Disease-2019-covid-19-and-Cardiovascular-Disease-A-Vicious-Circle_1585652470.pdf

  63. Touyz RM, Li H, Delles C. ACE2 the Janus-faced protein - from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19. Clin Sci (Lond). 2020;134(7):747-50.

  64. Henry C, Zaizafoun M, Stock E, Ghamande S, Ar-roliga AC, White HD. Impact of angiotensin-con-verting enzyme inhibitors and statins on viral pneumonia. Proc (Bayl Univ Med Cent). 2018; 31(4):419-23.

  65. Guo J, Huang Z, Lin L, Lv J. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angioten-sin-Converting Enzyme Inhibitors/Angiotensin Re-ceptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infec-tion. J Am Heart Assoc [Internet]. 2020 [Online 1 Apr 2020];9(7):e016219. Available at: https://doi.org/10.1161/jaha.120.016219

  66. South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol. 2020;318(5):H1084-90.

  67. Sanchis-Gomar F, Lavie CJ, Perez-Quilis C, Henry BM, Lippi G. Angiotensin-Converting Enzyme 2 and antihypertensives (angiotensin receptor blockers and angiotensin-converting enzyme in-hibitors) in Coronavirus Disease 2019. Mayo Clin Proc [Internet]. 2020 [Online 30 Mar 2020]. Avail-able at: https://doi.org/10.1016/j.mayocp.2020.03.026

  68. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting en-zyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11(8):875-9.

  69. Danser AHJ, Epstein M, Batlle D. Renin-Angioten- sin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers. Hyperten-sion [Internet]. 2020. [Online 25 Mar 2020]. Avail-able at: https://doi.org/10.1161/hypertensionaha.120.15082

  70. 70.Chapman AR, Bularga A, Mills NL. High-Sensi-tivity cardiac troponin can be an ally in the fight against COVID-19. Circulation [Internet]. 2020. [Online 6 Abr 2020]. Available at: http://doi.org/10.1161/CIRCULATIONAHA.120.047008

  71. Wang J, Xu H, Yang X, Zhao D, Liu S, Sun X, et al. Cardiac complications associated with the influ-enza viruses A subtype H7N9 or pandemic H1N1 in critically ill patients under intensive care. Braz J Infect Dis. 2017;21(1):12-8.




2020     |     www.medigraphic.com